Advertisement

Topics

Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis

10:13 EDT 15 Sep 2017 | Medscape

The drug selectively targets IL-23, a key driver of the immune inflammatory response in patients with psoriasis.
International Approvals

Original Article: Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis

NEXT ARTICLE

More From BioPortfolio on "Guselkumab (Tremfya) Gets CHMP Backing for Plaque Psoriasis"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...